ReviewSchizophrenia research and treatment2016
Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.
Review in Schizophrenia research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Drug Repurposing: Insights into Current Advances and Future Applications.Current medicinal chemistry · 2025Review
- Natural Plant Materials as a Source of Neuroprotective Peptides.Current medicinal chemistry · 2024Review
- Review
- Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia-A Systematic Review.Journal of clinical medicine · 2023Review
- A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.Experimental brain research · 2022Review
- Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders.Pharmaceutics · 2022Review
- Knowledge-based approaches to drug discovery for rare diseases.Drug discovery today · 2022Review
- Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues.Frontiers in pharmacology · 2022Review
- Insights into the roles of bacterial infection and antibiotics in Parkinson's disease.Frontiers in cellular and infection microbiology · 2022Review
- Neuroscientific Basis of Treatment for Substance Use Disorders.Noro psikiyatri arsivi · 2022Review
- Bioactive metabolites ofFood science & nutrition · 2021Article
- Article
- Incorporation of Sulfonamide Moiety into Biguanide Scaffold Results in Apoptosis Induction and Cell Cycle Arrest in MCF-7 Breast Cancer Cells.International journal of molecular sciences · 2021Article
- Central norepinephrine transmission is required for stress-induced repetitive behavior in two rodent models of obsessive-compulsive disorder.Psychopharmacology · 2020Article
- Loss of MicroRNA-137 Impairs the Homeostasis of Potassium in Neurons via KCC2.Experimental neurobiology · 2020Article
- Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis.Frontiers in immunology · 2020Review
- Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats.Journal of inflammation research · 2020Article
- Challenges for Drug Repurposing in the COVID-19 Pandemic Era.Frontiers in pharmacology · 2020Review
- Drug repurposing: a promising tool to accelerate the drug discovery process.Drug discovery today · 2019Review
- Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review.Frontiers in neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Better the drugs you know than the drugs you do not know. Drug repurposing is a promising, fast, and cost effective method that can overcome traditional de novo drug discovery and development challenges of targeting neuropsychiatric and other disorders. Drug discovery and development targeting neuropsychiatric disorders are complicated because of the limitations in understanding pathophysiological phenomena. In addition, traditional de novo drug discovery and development are risky, expensive, and time-consuming processes. One alternative approach, drug repurposing, has emerged taking advantage of off-target effects of the existing drugs. In order to identify new opportunities for the existing drugs, it is essential for us to understand the mechanisms of action of drugs, both biologically and pharmacologically. By doing this, drug repurposing would be a more effective method to develop drugs against neuropsychiatric and other disorders. Here, we review the difficulties in drug discovery and development in neuropsychiatric disorders and the extent and perspectives of drug repurposing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.